source
- SK Biopharma pens $795M deal to usher Biohaven’s epilepsy therapy towards hoped-for 2029 launchSK Biopharmaceuticals has strengthened its epilepsy offering by paying $350 million upfront to help speed Biohaven’s Kv7 ion channel activator on its way to market.Fierce Biotech · 13h ago↗ source
- Percutaneous Catheter Recall: Boston Scientific Removes ENROUTE Transcarotid Neuroprotection SystemENROUTE Transcarotid Neuroprotection Systems may have arterial sheath tip separation or partial tip separation during use.fda medwatch · 13h ago↗ source
- FDA expands Jazz's Ziihera use to frontline gastric cancerFDA granted approval for Jazz Pharmaceuticals' bispecific antibody Ziihera as a frontline treatment for certain gastric cancer patients. This is the first time Ziihera will be marketed to newly di…